bristol-myers-squibb-otsuka-pharmaceutical-europe-ltd

Médias

Six-Year Follow-Up Data for SPRYCEL®▼ (dasatinib) 100 mg Once Daily Demonstrates 71 Percent Overall Survival in Patients with Chronic-Phase Chronic Myeloid Leukaemia Resistant or Intolerant to Imatinib